Protara Therapeutics Stock Buy Hold or Sell Recommendation
| TARA Stock | USD 2.94 0.34 13.08% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Protara Therapeutics is 'Cautious Hold'. Macroaxis provides Protara Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding TARA positions.
Check out Protara Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide. In addition, we conduct extensive research on individual companies such as Protara and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Protara Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Protara |
Execute Protara Therapeutics Buy or Sell Advice
The Protara recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Protara Therapeutics. Macroaxis does not own or have any residual interests in Protara Therapeutics or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Protara Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Cautious Hold
Market Performance | Good | Details | |
Volatility | Very risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | About Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Protara Therapeutics Trading Alerts and Improvement Suggestions
| Protara Therapeutics appears to be risky and price may revert if volatility continues | |
| Net Loss for the year was (40.42 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Protara Therapeutics currently holds about 98.46 M in cash with (37.56 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.74, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from simplywall.st: Disposition of 500 shares by Opaleye Management Inc. of Protara Therapeutics at 3.0021 subject to Rule 16b-3 |
Protara Therapeutics Returns Distribution Density
The distribution of Protara Therapeutics' historical returns is an attempt to chart the uncertainty of Protara Therapeutics' future price movements. The chart of the probability distribution of Protara Therapeutics daily returns describes the distribution of returns around its average expected value. We use Protara Therapeutics price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Protara Therapeutics returns is essential to provide solid investment advice for Protara Therapeutics.
| Mean Return | 0.60 | Value At Risk | -4.98 | Potential Upside | 8.67 | Standard Deviation | 4.31 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Protara Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Protara Stock Institutional Investors
| Shares | Oppenheimer & Co Inc | 2024-09-30 | 179.1 K | Geode Capital Management, Llc | 2024-09-30 | 170 K | Ikarian Capital, Llc | 2024-09-30 | 155.7 K | Blackrock Inc | 2024-06-30 | 115.3 K | Woodline Partners Lp | 2024-06-30 | 100 K | Two Sigma Advisers, Llc | 2024-06-30 | 80.5 K | Marshall Wace Asset Management Ltd | 2024-06-30 | 77.4 K | Bridgeway Capital Management, Llc | 2024-09-30 | 49.2 K | Lpl Financial Corp | 2024-09-30 | 46 K | Ra Capital Management, Llc | 2024-09-30 | 1.9 M | Opaleye Management Inc | 2024-09-30 | 1.7 M |
Protara Therapeutics Cash Flow Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Investments | 2.5M | 2.8M | (97.6M) | 15.0M | 20.2M | 21.3M | |
| Change In Cash | (13.2M) | 168.8M | (132.9M) | (11.6M) | 15.5M | 16.2M | |
| Free Cash Flow | (15.7M) | (24.3M) | (35.1M) | (26.6M) | (37.6M) | (39.5M) | |
| Depreciation | 279K | 196K | 117K | 248K | 341K | 181.9K | |
| Other Non Cash Items | (4K) | 9.9M | 1.7M | 32.0M | 569K | 540.6K | |
| Capital Expenditures | 16K | 884K | 596K | 120K | 45K | 42.8K | |
| Net Income | (15.0M) | (34.0M) | (47.3M) | (66.0M) | (40.4M) | (42.4M) | |
| End Period Cash Flow | 6.2M | 169.4M | 36.5M | 24.9M | 40.3M | 50.9M | |
| Change To Netincome | 943K | 9.7M | 12.1M | 38.7M | 44.5M | 46.7M |
Protara Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Protara Therapeutics or Biotechnology sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Protara Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Protara stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.56 | |
β | Beta against Dow Jones | 0.23 | |
σ | Overall volatility | 4.33 | |
Ir | Information ratio | 0.11 |
Protara Therapeutics Volatility Alert
Protara Therapeutics shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Protara Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Protara Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Protara Therapeutics Fundamentals Vs Peers
Comparing Protara Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Protara Therapeutics' direct or indirect competition across all of the common fundamentals between Protara Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Protara Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Protara Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Protara Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Protara Therapeutics to competition |
| Fundamentals | Protara Therapeutics | Peer Average |
| Return On Equity | -0.46 | -0.31 |
| Return On Asset | -0.28 | -0.14 |
| Current Valuation | (16.11 M) | 16.62 B |
| Shares Outstanding | 20.63 M | 571.82 M |
| Shares Owned By Insiders | 6.12 % | 10.09 % |
| Shares Owned By Institutions | 51.10 % | 39.21 % |
| Number Of Shares Shorted | 2.74 M | 4.71 M |
| Price To Book | 0.74 X | 9.51 X |
| EBITDA | (43.27 M) | 3.9 B |
| Net Income | (40.42 M) | 570.98 M |
| Cash And Equivalents | 98.46 M | 2.7 B |
| Cash Per Share | 8.74 X | 5.01 X |
| Total Debt | 5.47 M | 5.32 B |
| Debt To Equity | 0.05 % | 48.70 % |
| Current Ratio | 28.94 X | 2.16 X |
| Book Value Per Share | 6.01 X | 1.93 K |
| Cash Flow From Operations | (37.56 M) | 971.22 M |
| Short Ratio | 14.46 X | 4.00 X |
| Earnings Per Share | (2.64) X | 3.12 X |
| Target Price | 29.5 | |
| Number Of Employees | 26 | 18.84 K |
| Beta | 1.79 | -0.15 |
| Market Capitalization | 60.65 M | 19.03 B |
| Total Asset | 78.95 M | 29.47 B |
| Retained Earnings | (200.38 M) | 9.33 B |
| Working Capital | 62.56 M | 1.48 B |
| Net Asset | 78.95 M |
Note: Disposition of 3500 shares by Opaleye Management Inc. of Protara Therapeutics at 2.4419 subject to Rule 16b-3 [view details]
Protara Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Protara . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Protara Therapeutics Buy or Sell Advice
When is the right time to buy or sell Protara Therapeutics? Buying financial instruments such as Protara Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Protara Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Wireless Thematic Idea Now
Wireless
Companies providing wireless technology and communication services. The Wireless theme has 46 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Wireless Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Protara Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. For information on how to trade Protara Stock refer to our How to Trade Protara Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Protara Therapeutics. If investors know Protara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Protara Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.64) | Return On Assets (0.28) | Return On Equity (0.46) |
The market value of Protara Therapeutics is measured differently than its book value, which is the value of Protara that is recorded on the company's balance sheet. Investors also form their own opinion of Protara Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Protara Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Protara Therapeutics' market value can be influenced by many factors that don't directly affect Protara Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Protara Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Protara Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Protara Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.